Osteoprotegerin and bone mineral density in hemodialysis patients: reply to letter by Ulivieri et al.

被引：0
|
作者：
Nakashima, A.
Yorioka, N.
机构：
[1] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ, Grad Sch Biomed Sci, Dept Adv Nephrol, Minami Ku, Hiroshima 7348551, Japan
来源：
OSTEOPOROSIS INTERNATIONAL | 2006年 / 17卷 / 12期
关键词：
Public Health; Bone Mineral Density; Negative Correlation; Alkaline Phosphatase; Bone Mineral;
D O I：
10.1007/s00198-006-0217-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1824 / 1824
页数：1
相关论文
共 50 条
  • [21] In reply to the letter to the editor 'in Reply to Gandaglia et al.' by De Bari et al.
    Gandaglia, G.
    Karakiewicz, P. I.
    Briganti, A.
    Menon, M.
    Sun, M.
    Abdollah, F.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1862 - 1863
  • [22] SERUM OSTEOPROTEGERIN LEVEL IS NEGATIVELY ASSOCIATED WITH BONE MINERAL DENSITY IN PATIENTS UNDERGOING HEMODIALYSIS
    Lu, Chia-Wen
    Hou, Jia-Sian
    Hsu, Bang-Gee
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1741 - 1741
  • [23] Osteoprotegerin and bone mineral density in hemodiafiltration patients
    Crisafulli, A
    Romeo, A
    Floccari, F
    Aloisi, E
    Atteritano, M
    Cincotta, M
    Aloisi, C
    Pizzoleo, MA
    Ruello, A
    Artemisia, A
    Valenti, A
    Frisina, N
    Teti, D
    Buemi, M
    RENAL FAILURE, 2005, 27 (05) : 531 - 539
  • [24] The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density: reply to Stepan et al.
    O. Bruyere
    J. Collette
    J.-Y. Reginster
    Osteoporosis International, 2010, 21 : 1039 - 1040
  • [25] The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density: reply to Stepan et al.
    Bruyere, O.
    Collette, J.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (06) : 1039 - 1040
  • [26] Reply to Wendling et al. about the article "The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis"
    Ju, Jihyeon
    Park, Sung-Hwan
    JOINT BONE SPINE, 2012, 79 (02) : 208 - 208
  • [27] Letter to the editor: In reply to Sansone et al.
    Langer, T.
    Pechmann, A.
    Wider, S.
    Kirschner, J.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2018, 22 (04) : 732 - 732
  • [28] Letter to the editor: Reply to Legare et al.
    van Westrhenen, R.
    Schulte, P. F. J.
    Sommer, I.
    MEDICAL HYPOTHESES, 2014, 83 (03) : 418 - 418
  • [29] Reply to Lorenz et al.: Osteoprotegerin in the central nervous system
    U. Naumann
    W. Wick
    R. Beschorner
    R. Meyermann
    M. Weller
    Acta Neuropathologica, 2004, 107 : 578 - 578
  • [30] Authors’ reply to letter of Vandijck et al.
    R. Raz
    Y. Ben-Israel
    D. Gronich
    E. Granot
    R. Colodner
    I. Visotzky
    European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25 (4): : 280 - 280
12345